Q-omics provides the consensus-scored LINC01186 profile across patient tissues and cancer cell-line models. LINC01186 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC01186 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, LINC01186 RNA expression shows 12,249 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where LINC01186 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01186 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01186 survival associations across molecular data types. LINC01186 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01186 RNA expression–survival associations across cancer types. High LINC01186 expression shows unfavorable associations in HNSC, KIRP, COAD, UCEC and PAAD, but favorable associations in MESO. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC01186 RNA expression.
This table summarizes LINC01186 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01186. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01186 shows lower tumor expression in KICH, BRCA and THCA and higher tumor expression in COAD, LIHC and BLCA. The COAD box plot shows higher LINC01186 RNA expression in tumor versus normal tissue (log2 FC = +0.971, t-test p < 0.001).
This table shows molecular features associated with LINC01186 in patient tissues and cancer cell lines. In patient samples, LINC01186 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
